QSP modeling For Gene Therapy

The development of new modality drugs, such as gene therapies and RNA-based treatments, presents significant challenges in accurately predicting their pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcomes. Traditional modeling approaches often lack the ability to simulate complex biological processes and account for variability, limiting their effectiveness in guiding dose optimization and treatment strategies.

We offer QSP (Quantitative Systems Pharmacology) service specifically designed to address the complexities of new modality drugs. For example, in our case study on CRISPR-Cas9 based gene editing therapy for transthyretin (ATTR) amyloidosis, our model mechanistically linked dose levels to treatment outcomes by simulating key biological processes, such as protein knockdown, clearance, and patient variability.

Our QSP services delivers robust, data-driven predictions to optimize dose levels, enhance clinical insights, and accelerate the development of new modality therapies. Our model provides in silico mechanistic validation to support clinical observations. This approach significantly reduces the need for extensive trial-and-error experiments and saves valuable time and resources while ensuring accurate predictions of treatment outcomes.